Frequently Asked Questions
The market is segmented based on , By Type (Epidemic (AIDS Associated) Kaposi Sarcoma, Classic (Mediterranean) Kaposi Sarcoma, Endemic (African) Kaposi Sarcoma, and Latrogenic (Transplant-Related) Kaposi Sarcoma), Treatment (Highly Active Antiretroviral Therapy (HAART), Radiation Therapy, Surgery, Cryosurgery, Chemotherapy, and Biological Therapy), Diagnostics (Bronchoscopy, Gastrointestinal Endoscopy, Biopsy, and Others), End-Users (Hospitals, Homecare, Speciality Centres, and Others) – Industry Trends and Forecast to 2031.
.
The Global Kaposi Sarcoma Market size was valued at USD 146.52 USD Million in 2023.
The Global Kaposi Sarcoma Market is projected to grow at a CAGR of 4.6% during the forecast period of 2024 to 2031.
The major players operating in the market include Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany).
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.
